API | Laronidase

Laronidase (Aldurazyme) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG repoDB

Active Ingredient History

NOW

Iduronidase, sold as Aldurazyme, is an enzyme with the systematic name glycosaminoglycan α-L-iduronohydrolase. It catalyses the hydrolysis of unsulfated α-L-iduronosidic linkages in dermatan sulfate. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

laronidase

hyaluronidase

hyaluronidase (ovine)

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$671.2300 - $871.0700

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (2)

Mucopolysaccharidoses

Mucopolysaccharidosis I (approved 2003)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Gaucher Disease (Phase 1)

Genetic Diseases, Inborn (Phase 3)

Lysosomal Storage Diseases (Phase 1)

Mucopolysaccharidoses (Phase 1)

Mucopolysaccharidosis I (Phase 4)

Mucopolysaccharidosis IV (Phase 1)

Ophthalmology (Phase 4)

Spinal Cord Compression (Phase 1)

Wolman Disease (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 19
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue